|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
Francois Guilhot
,
Françoise Rigal-Huguet
,
Joëlle Guilhot
,
Agnès-Paule Guerci-Bresler
,
Frédéric Maloisel
et al.
Journal articles
hal-03122967v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|